Veronika Bachanová

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster, Michael Bishop, Constantine S. Tam et al. · New England Journal of Medicine · 2018 · 4K citations · Full text

Medicine, Hematology, Oncology +15

Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial

Manali Kamdar, Scott R. Solomon, Jon Arnason et al. · The Lancet · 2022 · 752 citations

Medicine, Oncology, Chemotherapy +13

Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial

Craig H. Moskowitz, Auayporn Nademanee, Tamás Masszi et al. · The Lancet · 2015 · 734 citations · Full text

Medicine, Immunology, Oncology +15

Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein

Veronika Bachanová, Sarah Cooley, Todd E. DeFor et al. · Blood · 2014 · 432 citations

Life Sciences, Hematology, Immunology +16

Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study

Jeremy S. Abramson, Scott R. Solomon, Jon Arnason et al. · Blood · 2022 · 368 citations · Full text

Medicine, Oncology, Pharmacotherapy +15